ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,264Medicare Part D Prescriptions Filled, Including Refills

Rank: 66 out of 1269

$516K Total Retail Price of All Prescriptions

Rank: 143 out of 1269

301 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
62% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 301 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

11% of this provider’s 301 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 7,935 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

34 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 506 407 1 4
LISINOPRIL 445 344 2 1
FUROSEMIDE 335 276 3 5
SIMVASTATIN 290 223 4 3
METOPROLOL TARTRATE 248 208 5 6
AMLODIPINE BESYLATE 237 229 6 2
CITALOPRAM HBR 225 168 7 21
TRAMADOL HCL 218 131 8 16
OMEPRAZOLE 208 129 9 8
GABAPENTIN 207 175 10 17
POTASSIUM CHLORIDE 182 156 11 26
WARFARIN SODIUM 138 131 12 12
SERTRALINE HCL 137 114 13 23
RISPERIDONE 137 137 13 43
ZOLPIDEM TARTRATE 136 109 15 19
AZITHROMYCIN 135 99 16 42
JANTOVEN 121 121 17 52
HYDROCODONE-ACETAMINOPHEN 116 112 S3 18 20
DONEPEZIL HCL 113 101 19 22
METFORMIN HCL 112 76 20 9
PRAVASTATIN SODIUM 110 73 21 11
METOPROLOL SUCCINATE 102 91 22 13
OXYCODONE-ACETAMINOPHEN 101 42 S2 23 44
LOSARTAN POTASSIUM 96 92 24 15
NAMENDA 96 84 24 38
LANTUS 92 74 26 39
RANITIDINE HCL 92 75 26 27
HYDROCHLOROTHIAZIDE 86 68 28 10
ENALAPRIL MALEATE 85 71 29 79
CIPROFLOXACIN HCL 84 66 30 66
GLIMEPIRIDE 82 76 31 57
MELOXICAM 78 56 32 68
GLYBURIDE 78 37 R 32 94
POLYETHYLENE GLYCOL 3350 74 63 34 50
ESCITALOPRAM OXALATE 72 72 35 58
CLOPIDOGREL 70 58 36 32
PRIMIDONE 69 57 37 209
QUINAPRIL HCL 68 56 38 167
ATORVASTATIN CALCIUM 66 66 39 7
ATENOLOL 60 38 40 14
SPIRONOLACTONE 59 38 41 77
CARBIDOPA-LEVODOPA 59 58 41 78
PROAIR HFA 58 16 43 61
TERAZOSIN HCL 57 56 44 111
JANUVIA 56 29 45 74
PANTOPRAZOLE SODIUM 55 45 46 18
DIOVAN 52 48 47 35
QUETIAPINE FUMARATE 51 29 48 53
DIGOXIN 51 50 48 62
RAMIPRIL 50 43 50 96
NITROGLYCERIN PATCH 50 49 50 114
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 5, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.